![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CCPG1 |
Gene summary for CCPG1 |
![]() |
Gene information | Species | Human | Gene symbol | CCPG1 | Gene ID | 9236 |
Gene name | cell cycle progression 1 | |
Gene Alias | CPR8 | |
Cytomap | 15q21.3 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9ULG6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9236 | CCPG1 | LZE4T | Human | Esophagus | ESCC | 9.27e-15 | 4.20e-01 | 0.0811 |
9236 | CCPG1 | LZE5T | Human | Esophagus | ESCC | 1.29e-04 | 6.96e-01 | 0.0514 |
9236 | CCPG1 | LZE7T | Human | Esophagus | ESCC | 1.29e-06 | 5.02e-01 | 0.0667 |
9236 | CCPG1 | LZE8T | Human | Esophagus | ESCC | 1.70e-11 | 3.24e-01 | 0.067 |
9236 | CCPG1 | LZE22T | Human | Esophagus | ESCC | 4.79e-04 | 3.01e-01 | 0.068 |
9236 | CCPG1 | LZE24T | Human | Esophagus | ESCC | 1.44e-05 | 3.11e-01 | 0.0596 |
9236 | CCPG1 | LZE6T | Human | Esophagus | ESCC | 7.02e-08 | 3.35e-01 | 0.0845 |
9236 | CCPG1 | P1T-E | Human | Esophagus | ESCC | 6.70e-07 | 5.66e-01 | 0.0875 |
9236 | CCPG1 | P2T-E | Human | Esophagus | ESCC | 7.73e-17 | 2.47e-01 | 0.1177 |
9236 | CCPG1 | P4T-E | Human | Esophagus | ESCC | 3.26e-13 | 4.41e-01 | 0.1323 |
9236 | CCPG1 | P5T-E | Human | Esophagus | ESCC | 9.03e-16 | 3.79e-01 | 0.1327 |
9236 | CCPG1 | P8T-E | Human | Esophagus | ESCC | 4.08e-49 | 1.01e+00 | 0.0889 |
9236 | CCPG1 | P9T-E | Human | Esophagus | ESCC | 3.00e-13 | 4.44e-01 | 0.1131 |
9236 | CCPG1 | P10T-E | Human | Esophagus | ESCC | 5.45e-10 | 2.07e-01 | 0.116 |
9236 | CCPG1 | P11T-E | Human | Esophagus | ESCC | 6.20e-17 | 7.16e-01 | 0.1426 |
9236 | CCPG1 | P12T-E | Human | Esophagus | ESCC | 4.26e-15 | 3.45e-01 | 0.1122 |
9236 | CCPG1 | P15T-E | Human | Esophagus | ESCC | 3.26e-05 | 2.74e-01 | 0.1149 |
9236 | CCPG1 | P16T-E | Human | Esophagus | ESCC | 3.29e-09 | 2.11e-01 | 0.1153 |
9236 | CCPG1 | P19T-E | Human | Esophagus | ESCC | 8.33e-05 | 7.29e-01 | 0.1662 |
9236 | CCPG1 | P20T-E | Human | Esophagus | ESCC | 2.44e-07 | 1.88e-01 | 0.1124 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0051098111 | Esophagus | ESCC | regulation of binding | 251/8552 | 363/18723 | 6.73e-20 | 8.46e-18 | 251 |
GO:004578710 | Esophagus | ESCC | positive regulation of cell cycle | 196/8552 | 313/18723 | 9.27e-10 | 2.24e-08 | 196 |
GO:004308715 | Esophagus | ESCC | regulation of GTPase activity | 183/8552 | 348/18723 | 5.34e-03 | 2.00e-02 | 183 |
GO:005109812 | Liver | Cirrhotic | regulation of binding | 148/4634 | 363/18723 | 9.14e-12 | 5.97e-10 | 148 |
GO:00457874 | Liver | Cirrhotic | positive regulation of cell cycle | 97/4634 | 313/18723 | 6.88e-03 | 3.38e-02 | 97 |
GO:005109822 | Liver | HCC | regulation of binding | 225/7958 | 363/18723 | 3.78e-14 | 2.37e-12 | 225 |
GO:004578711 | Liver | HCC | positive regulation of cell cycle | 172/7958 | 313/18723 | 5.29e-06 | 6.58e-05 | 172 |
GO:005109820 | Oral cavity | OSCC | regulation of binding | 212/7305 | 363/18723 | 3.88e-14 | 2.15e-12 | 212 |
GO:00457879 | Oral cavity | OSCC | positive regulation of cell cycle | 173/7305 | 313/18723 | 3.28e-09 | 7.44e-08 | 173 |
GO:004308710 | Oral cavity | OSCC | regulation of GTPase activity | 165/7305 | 348/18723 | 7.94e-04 | 4.27e-03 | 165 |
GO:005109819 | Prostate | Tumor | regulation of binding | 122/3246 | 363/18723 | 2.86e-14 | 3.63e-12 | 122 |
GO:004578714 | Prostate | Tumor | positive regulation of cell cycle | 81/3246 | 313/18723 | 8.45e-05 | 8.46e-04 | 81 |
GO:004308713 | Prostate | Tumor | regulation of GTPase activity | 88/3246 | 348/18723 | 1.04e-04 | 1.00e-03 | 88 |
GO:0051098113 | Thyroid | PTC | regulation of binding | 195/5968 | 363/18723 | 3.21e-18 | 3.37e-16 | 195 |
GO:004578718 | Thyroid | PTC | positive regulation of cell cycle | 144/5968 | 313/18723 | 9.93e-08 | 1.99e-06 | 144 |
GO:004308718 | Thyroid | PTC | regulation of GTPase activity | 148/5968 | 348/18723 | 1.63e-05 | 1.71e-04 | 148 |
GO:1904424 | Thyroid | PTC | regulation of GTP binding | 11/5968 | 15/18723 | 1.19e-03 | 6.84e-03 | 11 |
GO:005109834 | Thyroid | ATC | regulation of binding | 203/6293 | 363/18723 | 1.18e-18 | 1.55e-16 | 203 |
GO:004578719 | Thyroid | ATC | positive regulation of cell cycle | 158/6293 | 313/18723 | 4.18e-10 | 1.14e-08 | 158 |
GO:004308719 | Thyroid | ATC | regulation of GTPase activity | 153/6293 | 348/18723 | 3.24e-05 | 2.68e-04 | 153 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CCPG1 | SNV | Missense_Mutation | novel | c.103A>T | p.Ser35Cys | p.S35C | Q9ULG6 | protein_coding | tolerated(0.22) | possibly_damaging(0.707) | TCGA-MN-A4N4-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CCPG1 | SNV | Missense_Mutation | c.364N>A | p.Val122Ile | p.V122I | Q9ULG6 | protein_coding | tolerated(0.47) | benign(0.036) | TCGA-22-5471-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
CCPG1 | SNV | Missense_Mutation | c.1313N>C | p.Leu438Pro | p.L438P | Q9ULG6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-56-8625-01 | Lung | lung squamous cell carcinoma | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD | |
CCPG1 | SNV | Missense_Mutation | c.346N>A | p.Glu116Lys | p.E116K | Q9ULG6 | protein_coding | deleterious(0) | possibly_damaging(0.521) | TCGA-60-2698-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | mithramycin | PD | |
CCPG1 | SNV | Missense_Mutation | novel | c.1409N>C | p.Gly470Ala | p.G470A | Q9ULG6 | protein_coding | tolerated(0.2) | probably_damaging(0.975) | TCGA-85-8580-01 | Lung | lung squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CCPG1 | SNV | Missense_Mutation | novel | c.687G>T | p.Met229Ile | p.M229I | Q9ULG6 | protein_coding | deleterious(0.04) | probably_damaging(0.99) | TCGA-94-8035-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unspecific | Complete Response | |
CCPG1 | SNV | Missense_Mutation | novel | c.968N>T | p.Ser323Leu | p.S323L | Q9ULG6 | protein_coding | tolerated(0.48) | benign(0.059) | TCGA-CN-4723-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CCPG1 | SNV | Missense_Mutation | novel | c.1510G>T | p.Val504Leu | p.V504L | Q9ULG6 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-CN-4730-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CCPG1 | SNV | Missense_Mutation | novel | c.948G>C | p.Lys316Asn | p.K316N | Q9ULG6 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-CV-7414-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CCPG1 | SNV | Missense_Mutation | c.2207N>G | p.His736Arg | p.H736R | Q9ULG6 | protein_coding | tolerated(0.15) | benign(0.271) | TCGA-KK-A59X-01 | Prostate | prostate adenocarcinoma | Male | <65 | 9 | Hormone Therapy | leuprolide | PD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |